Aspire Biopharma Holdings (ASBP) Research & Development (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Research & Development for 3 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 244.31% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $2.1 million, a 208.52% increase from a year earlier, with the FY2025 full-year figure at $923914.0, up 540.02% from the prior year.
• Research & Development was $1.2 million for Q2 2026 at Aspire Biopharma Holdings, up from $334739.0 in the prior quarter.
• Over five years, Research & Development peaked at $1.2 million in Q2 2026 and troughed at $10500.0 in Q2 2024.
• A 3-year average of $284612.4 and a median of $181564.0 in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 3260.83% in 2025 and increased 27.23% in 2026, its largest moves.
• Over 3 years, Research & Development stood at $40012.0 in 2024, then jumped by 150.01% to $100035.0 in 2025, then jumped by 1114.6% to $1.2 million in 2026.
• The last three Research & Development figures came in at $1.2 million (Q2 2026), $334739.0 (Q1 2026), and $100035.0 (Q4 2025), per Business Quant data.